Latest Information Update: 24 May 2001
At a glance
- Originator Genentech
- Class Antineoplastics
- Mechanism of Action Somatotropin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 18 Apr 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 21 Jun 1995 This profile is new.